All contributors
Onconephrology contributor
Gertz, Morie A
Primarily MGRS & paraprotein kidney disease#5 of 47 recognizedHonor roll
- #5 in MGRS & paraprotein kidney disease
87
Clinical papers
5,598
Citations (iCite)
9 / 26
First / senior author
2002–2026
Active years
Output over time
Clinical corpus papers per year — peak 9 in 2020.
- 2002: 1 paper
- 2003: 4 papers
- 2004: 2 papers
- 2005: 7 papers
- 2006: 1 paper
- 2007: 3 papers
- 2008: 1 paper
- 2009: 2 papers
- 2010: 2 papers
- 2011: 2 papers
- 2012: 5 papers
- 2013: 4 papers
- 2015: 5 papers
- 2016: 4 papers
- 2017: 4 papers
- 2018: 6 papers
- 2019: 6 papers
- 2020: 9 papers
- 2021: 3 papers
- 2022: 3 papers
- 2023: 5 papers
- 2024: 4 papers
- 2025: 3 papers
- 2026: 1 paper
20022026
Subfield mix
Clinical papers by onconephrology subfield (a paper can count in more than one).
MGRS & paraprotein kidney disease73
Myeloma cast nephropathy46
Onco-nephrology (general)3
Anticancer drug nephrotoxicity1
Tumor lysis & electrolytes1
Frequent collaborators
Other recognized contributors who most often share corpus papers with Gertz (shared-paper count).
Agents they study
Catalog agents whose clinical kidney literature lists Gertz among the leading contributors.
Verify
Representative recent papers, and this author’s full PubMed bibliography.
A code-tallied bibliometric profile from PubMed + NIH iCite, restricted to human/clinical papers across a 15,329-article corpus (regenerated 2026-08-02). Recognition of published contribution — not a verdict on merit or influence, and not medical advice.